Arcadia Biosciences Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
RKDA$0.16-3.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $3,317 | $6,518 |
| Short-term investments | 5,184 | 5,124 |
| Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of March 31, 2024 and December 31, 2023 | 760 | 514 |
| Inventories — current | 1,831 | 1,958 |
| Assets held for sale | 15 | 51 |
| Prepaid expenses and other current assets | 535 | 807 |
| Total current assets | 11,642 | 14,972 |
| Property and equipment, net | 328 | 384 |
| Right of use asset | 695 | 792 |
| Inventories — noncurrent | 3,178 | 3,354 |
| Intangible assets, net | 39 | 39 |
| Other noncurrent assets | 164 | 164 |
| Total assets | $16,046 | $19,705 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,732 | $2,410 |
| Amounts due to related parties | 75 | 58 |
| Operating lease liability — current | 801 | 852 |
| Other current liabilities | 270 | 270 |
| Total current liabilities | 2,878 | 3,590 |
| Operating lease liability — noncurrent | 21 | 155 |
| Common stock warrant and option liabilities | 664 | 1,257 |
| Other noncurrent liabilities | 2,000 | 2,000 |
| Total liabilities | 5,563 | 7,002 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value—150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 1,362,840 and 1,285,337 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 65 | 65 |
| Additional paid-in capital | 284,658 | 284,515 |
| Accumulated other comprehensive income | 161 | 101 |
| Accumulated deficit | (274,263) | (271,840) |
| Total stockholders’ equity | 10,621 | 12,841 |
| Non-controlling interest | (138) | (138) |
| Total stockholders' equity | 10,483 | 12,703 |
| Total liabilities and stockholders’ equity | $16,046 | $19,705 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.